IRVING, Texas, Jan. 5, 2017– Caris Life Sciences®, a leading innovator in molecular science, today announced that David D. Halbert, Chairman and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 10:30 a.m. PT in San Francisco, Calif. Mr. Halbert will provide a corporate update and discuss the latest developments for the company’s proprietary molecular science platforms, ADAPT Biotargeting System™ and Caris Molecular Intelligence®, in addition to taking questions from the audience.
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. With more than 110,000 clinical cases, Caris Molecular Intelligence®, the company’s patented and proprietary product offering, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. The company is also developing the ADAPT Biotargeting System™, which is a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring for cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.
Caris Life Sciences Media Relations & Corporate Affairs